

Michele Magni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7607727/publications.pdf>

Version: 2024-02-01

57
papers

5,564
citations

201575

27
h-index

161767

54
g-index

57
all docs

57
docs citations

57
times ranked

6722
citing authors

#	ARTICLE	IF	CITATIONS
1	Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. <i>Blood</i> , 2002, 99, 3838-3843.	0.6	2,907
2	High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 1997, 336, 1290-1298.	13.9	460
3	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.	0.6	201
4	Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). <i>Blood</i> , 2003, 102, 749-755.	0.6	193
5	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Clinical Cancer Research</i> , 2009, 15, 4415-4422.	3.2	189
6	Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 814-824.	0.8	151
7	Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death. <i>Cancer Research</i> , 2010, 70, 9062-9072.	0.4	126
8	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009, 113, 18-27.	0.6	99
9	Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination. <i>Clinical Cancer Research</i> , 2004, 10, 5381-5390.	3.2	98
10	High-Dose Yttrium-90- ¹²⁵ Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 5175-5182.	0.8	68
11	Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innovative nei Linfomi Survey. <i>Journal of Clinical Oncology</i> , 2008, 26, 3166-3175.	0.8	68
12	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). <i>Leukemia</i> , 2007, 21, 1802-1811.	3.3	66
13	High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease - A 6-year update. <i>Annals of Oncology</i> , 1993, 4, 889-891.	0.6	61
14	Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. <i>Blood</i> , 2002, 100, 1104-1105.	0.6	58
15	Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1270-1276.	2.0	55
16	Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. <i>Journal of Clinical Oncology</i> , 1992, 10, 1955-1962.	0.8	48
17	High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. <i>Bone Marrow Transplantation</i> , 2002, 30, 725-732.	1.3	47
18	Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. <i>Blood</i> , 2004, 103, 3287-3295.	0.6	47

#	ARTICLE	IF	CITATIONS
19	Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. <i>Gene Therapy</i> , 1998, 5, 465-472.	2.3	38
20	The Anti-“Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice. <i>Cancer Research</i> , 2006, 66, 1799-1808.	0.4	37
21	Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. <i>Leukemia Research</i> , 2002, 26, 1131-1133.	0.4	36
22	High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. <i>British Journal of Haematology</i> , 2004, 126, 815-820.	1.2	35
23	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 783-791.	0.4	35
24	Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. <i>Leukemia and Lymphoma</i> , 2010, 51, 1251-1259.	0.6	34
25	Antitumor Activity of Human CD34+ Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. <i>Human Gene Therapy</i> , 2006, 17, 1225-1240.	1.4	33
26	Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-“related apoptosis-inducing ligand target both tumor cells and tumor vasculature. <i>Blood</i> , 2010, 115, 2231-2240.	0.6	32
27	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. <i>Blood</i> , 2011, 118, 4421-4430.	0.6	30
28	Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2002, 29, S10-S13.	1.3	28
29	High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. <i>Bone Marrow Transplantation</i> , 2009, 43, 509-511.	1.3	25
30	Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. <i>Bone Marrow Transplantation</i> , 1999, 23, 323-327.	1.3	19
31	Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting. <i>Cancer</i> , 2003, 98, 983-992.	2.0	18
32	IFN-γ Enhances the Antimyeloma Activity of the Fully Human Anti-“Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. <i>Cancer Research</i> , 2007, 67, 3269-3275.	0.4	18
33	Pleiotropic antitumor effects of the pan-“HDAC inhibitor ITF2357 against c-“Myc-overexpressing human B-cell non-“Hodgkin lymphomas. <i>International Journal of Cancer</i> , 2014, 135, 2034-2045.	2.3	18
34	Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex. <i>British Journal of Haematology</i> , 2000, 111, 344-350.	1.2	18
35	Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice. <i>Cancer Research</i> , 2002, 62, 6152-7.	0.4	18
36	Recombinant Adenoviral Vector-LipofectAMINE Complex for Gene Transduction into Human T Lymphocytes. <i>Human Gene Therapy</i> , 1999, 10, 1875-1884.	1.4	17

#	ARTICLE	IF	CITATIONS
37	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. <i>Annals of Oncology</i> , 2015, 26, 167-172.	0.6	17
38	Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose ⁹⁰ Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. <i>Journal of Clinical Oncology</i> , 2013, 31, 2974-2976.	0.8	14
39	Placental Growth Factor-1 Potentiates Hematopoietic Progenitor Cell Mobilization Induced by Granulocyte Colony-Stimulating Factor in Mice and Nonhuman Primates. <i>Stem Cells</i> , 2007, 25, 252-261.	1.4	12
40	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 332.e19-332.e24.	0.8	12
41	Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection. <i>Haematologica</i> , 2003, 88, 1396-404.	1.7	11
42	Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. <i>Bone Marrow Transplantation</i> , 2014, 49, 485-491.	1.3	10
43	Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. <i>Bone Marrow Transplantation</i> , 2010, 45, 1119-1120.	1.3	9
44	Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. <i>Future Oncology</i> , 2014, 10, 2569-2578.	1.1	8
45	Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor. <i>Experimental Hematology</i> , 2004, 32, 68-75.	0.2	7
46	Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s). <i>Stem Cells</i> , 1993, 11, 72-75.	1.4	5
47	Highly efficient gene transfer into mobilized CD34+ hematopoietic cells using serotype-5 adenoviral vectors and BoosterExpress Reagent. <i>Experimental Hematology</i> , 2007, 35, 888-897.	0.2	5
48	Practical aspects of flow cytometry to guide large-scale collection of circulating hematopoietic progenitors for autologous transplantation in cancer patients. <i>International Journal of Cell Cloning</i> , 1992, 10, 26-29.	1.6	4
49	Radioimmunotherapy and secondary leukemia: A case report. <i>Leukemia Research</i> , 2010, 34, e1-e4.	0.4	4
50	Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.		4
51	Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 196-202.e1.	0.9	3
52	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021, 56, 2606-2609.	1.3	3
53	Correspondence. <i>Experimental Hematology</i> , 1999, 27, 386-387.	0.2	2
54	Successful second autologous engraftment after long duration storage of hematopoietic stem cells. <i>Bone Marrow Transplantation</i> , 2013, 48, 1480-1481.	1.3	2

#	ARTICLE	IF	CITATIONS
55	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood, 2000, 96, 864-869.	0.6	1
56	Large-scale feasibility of gene transduction into human CD34 ⁺ cell-derived dendritic cells by adenoviral/polycation complex. British Journal of Haematology, 2000, 111, 344-350.	1.2	0
57	Antitumor Activity of Human CD34+Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Human Gene Therapy, 2006, .	1.4	0